Nationwide treatment and outcomes of perihilar cholangiocarcinoma.
cholangiocarcinoma
klatskin tumour
treatment outcome
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
06
02
2021
received:
25
12
2020
accepted:
17
02
2021
pubmed:
1
3
2021
medline:
3
8
2021
entrez:
28
2
2021
Statut:
ppublish
Résumé
Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex multidisciplinary management. All known data are almost exclusively derived from expert centres. This study aimed to analyse the outcomes of patients with pCCA in a nationwide cohort. Data on all patients diagnosed with pCCA in the Netherlands between 2010 and 2018 were obtained from the Netherlands Cancer Registry. Data included type of hospital of diagnosis and the received treatment. Outcomes included the type of treatment and overall survival. A total of 2031 patients were included and the median overall survival for the overall cohort was 5.2 (95% CI 4.7-5.7) months. Three-hundred-ten (15%) patients underwent surgical resection, 271 (13%) underwent palliative systemic treatment, 21 (1%) palliative local anti-cancer treatment and 1429 (70%) underwent best supportive care. These treatments resulted in a median overall survival of 29.6 (95% CI 25.2-34.0), 12.2 (95% CI 11.0-13.3), 14.5 (95%CI 8.2-20.8) and 2.9 (95% CI 2.6-3.2) months respectively. Resection rate was 13% in patients who were diagnosed in non-academic and 32% in academic centres (P < .001), which resulted in a survival difference in favour of academic centres. Median overall survival was 9.7 (95% CI 7.7-11.7) months in academic centres compared to 4.9 (95% CI 4.3-5.4) months in non-academic centres (P < .001). In patients with pCCA, resection rate and overall survival were higher for patients who were diagnosed in academic centres. These results show population-based outcomes of pCCA and highlight the importance of regional collaboration in the treatment of these patients.
Sections du résumé
BACKGROUND
Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex multidisciplinary management. All known data are almost exclusively derived from expert centres. This study aimed to analyse the outcomes of patients with pCCA in a nationwide cohort.
METHODS
Data on all patients diagnosed with pCCA in the Netherlands between 2010 and 2018 were obtained from the Netherlands Cancer Registry. Data included type of hospital of diagnosis and the received treatment. Outcomes included the type of treatment and overall survival.
RESULTS
A total of 2031 patients were included and the median overall survival for the overall cohort was 5.2 (95% CI 4.7-5.7) months. Three-hundred-ten (15%) patients underwent surgical resection, 271 (13%) underwent palliative systemic treatment, 21 (1%) palliative local anti-cancer treatment and 1429 (70%) underwent best supportive care. These treatments resulted in a median overall survival of 29.6 (95% CI 25.2-34.0), 12.2 (95% CI 11.0-13.3), 14.5 (95%CI 8.2-20.8) and 2.9 (95% CI 2.6-3.2) months respectively. Resection rate was 13% in patients who were diagnosed in non-academic and 32% in academic centres (P < .001), which resulted in a survival difference in favour of academic centres. Median overall survival was 9.7 (95% CI 7.7-11.7) months in academic centres compared to 4.9 (95% CI 4.3-5.4) months in non-academic centres (P < .001).
CONCLUSIONS
In patients with pCCA, resection rate and overall survival were higher for patients who were diagnosed in academic centres. These results show population-based outcomes of pCCA and highlight the importance of regional collaboration in the treatment of these patients.
Identifiants
pubmed: 33641214
doi: 10.1111/liv.14856
pmc: PMC8359996
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1945-1953Informations de copyright
© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Ann Surg Oncol. 2020 Dec;27(13):5209-5221
pubmed: 32495286
Br J Surg. 2019 Oct;106(11):1523-1529
pubmed: 31339558
Surgery. 2018 Nov;164(5):1023-1029
pubmed: 30082134
HPB (Oxford). 2017 Nov;19(11):966-971
pubmed: 28754366
Eur J Cancer. 1998 Jan;34(1):33-46
pubmed: 9624235
BJS Open. 2020 Jun;4(3):449-455
pubmed: 32181590
J Clin Oncol. 2000 Jul;18(14):2780-7
pubmed: 10894879
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Surgery. 1994 May;115(5):597-603
pubmed: 7513906
Ann Surg Oncol. 2016 Dec;23(Suppl 5):904-910
pubmed: 27586005
Liver Int. 2021 Aug;41(8):1945-1953
pubmed: 33641214
Int J Epidemiol. 1993 Jun;22(3):369-76
pubmed: 8359950
Br J Surg. 2020 Jun;107(7):917-926
pubmed: 32207856
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
pubmed: 11573044
Gastrointest Endosc. 2002 Dec;56(6):835-41
pubmed: 12447294
Ann Surg. 2012 Nov;256(5):697-704; discussion 704-5
pubmed: 23095612
Surgery. 2019 May;165(5):918-928
pubmed: 30871811
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
J Am Coll Surg. 2017 Sep;225(3):387-394
pubmed: 28687509
Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14
pubmed: 22504095
BMC Gastroenterol. 2012 Aug 09;12:103
pubmed: 22873816
J Hepatobiliary Pancreat Sci. 2020 Oct;27(10):700-711
pubmed: 32786134
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Eur J Cancer. 2015 Sep;51(13):1694-703
pubmed: 26066735
United European Gastroenterol J. 2017 Jun;5(4):519-526
pubmed: 28588883
J Am Coll Surg. 2012 Sep;215(3):343-55
pubmed: 22749003
Am J Gastroenterol. 2014 Dec;109(12):1881-90
pubmed: 25384902
Ann Surg Oncol. 2021 Mar;28(3):1483-1492
pubmed: 32901308
J Surg Oncol. 2018 Sep;118(3):469-476
pubmed: 30132904
J Gastrointest Oncol. 2017 Apr;8(2):314-323
pubmed: 28480070
Oncology (Williston Park). 2005 Jul;19(8):1057-63; discussion 1063-4, 1069
pubmed: 16131047
J Hepatobiliary Pancreat Sci. 2013 Mar;20(3):324-31
pubmed: 22706427
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Ann Surg Oncol. 2020 Jul;27(7):2311-2318
pubmed: 32103419
Anticancer Res. 2020 Jun;40(6):3013-3030
pubmed: 32487595
J Am Coll Surg. 2016 Aug;223(2):321-331.e1
pubmed: 27063572
Gut Liver. 2009 Dec;3(4):298-305
pubmed: 20431764
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Hepatobiliary Pancreat Sci. 2019 Nov;26(11):490-502
pubmed: 31520452
Hepatogastroenterology. 2006 Jan-Feb;53(67):21-7
pubmed: 16506370